Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
SUNHO（China）BioPharmaceutical CO., Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06504732CT.gov To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer | — | Recruiting | — | — | — |
NCT05152147CT.gov A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | — | Active Not Recruiting | — | — | — |
NCT03615326CT.gov Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | — | Completed | — | — | — |
NCT01649271CT.gov Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastric Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab (this asset) | SUNHO（China）BioPharmaceutical CO., Ltd. | P3 | BB · 65 |
| Fluorouracilum | Seagen, a wholly owned subsidiary of Pfizer | P4 | BBB |
| Capecitabine | SUNHO（China）BioPharmaceutical CO., Ltd. | P3 | BB |
| Oxaliplatin | SUNHO（China）BioPharmaceutical CO., Ltd. | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Jazz Pharmaceuticals | P3 | BB |
| Pembrolizumab | Merck Sharp & Dohme LLC | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Triglycerides,Medium Chain | Wei Zhou | P4 | BB |
| S-1 | Merck Sharp & Dohme LLC | P3 | BB |
+42 more in the Gastric Neoplasm cohort
Other indications for Trastuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 76 |
| Inflammatory Breast Carcinoma | — | P3 | BBB · 74 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab in Gastric Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/trastuzumab-gastric-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →